KINNATE BIOPHARMA INC (KNTE) Forecast, Price Target & Analyst Ratings

NASDAQ:KNTE • US49705R1059

2.65 USD

-0.01 (-0.38%)

At close: Apr 2, 2024

2.65 USD

0 (0%)

After Hours: 4/2/2024, 8:25:40 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KINNATE BIOPHARMA INC (KNTE).

Consensus Price Target

Price Target

$2.41

-9.04% Downside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 9, 2024
Period: Q1 / 2024
EPS Estimate: -$0.37
Revenue Estimate

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

78.00%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$2.41

Upside

-9.04%

From current price of $2.65 to mean target of $2.41, Based on 10 analyst forecasts

Low

$2.02

Median

$2.55

High

$2.72

Price Target Revisions

1 Month

13.35%

3 Months

-12.47%

Price Target Summary

10 Wall Street analysts provided a forecast for the next 12 months for KNTE. The average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65.

The average price target has been revised downward by 12.47% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

78.00%

KNTE was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about KNTE.

In the previous month the buy percentage consensus was at a similar level.

KNTE was analyzed by 10 analysts. More opinions would make the average more meaningful.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2024-02-26	Stifel	Maintains	Hold -> Hold
2024-01-17	Wedbush	Reiterate	Neutral -> Neutral
2023-09-19	Wedbush	Downgrade	Outperform -> Neutral
2023-09-19	Piper Sandler	Downgrade	Overweight -> Neutral
2023-09-19	Jefferies	Maintains	Buy -> Buy
2023-09-19	HC Wainwright & Co.	Downgrade	Buy -> Neutral
2023-08-15	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-06-08	HC Wainwright & Co.	Reiterate	Buy -> Buy
2023-05-18	HC Wainwright & Co.	Maintains	Buy -> Buy
2023-05-12	Stifel	Maintains	Hold -> Hold
2023-05-12	Wedbush	Reiterate	Outperform -> Outperform
2023-04-20	HC Wainwright & Co.	Maintains	Buy
2023-04-19	Goldman Sachs	Maintains	Buy
2023-04-18	Goldman Sachs	Maintains	Buy
2023-03-20	HC Wainwright & Co.	Reiterate	Buy
2023-03-16	Stifel	Maintains	Hold
2023-03-16	Wedbush	Maintains	Outperform
2022-11-17	Stifel	Downgrade	Buy -> Hold
2022-07-28	HC Wainwright & Co.	Initiate	Buy
2022-05-24	Goldman Sachs	Maintains	Buy
2022-05-19	Piper Sandler	Maintains	Overweight
2021-09-27	Jefferies	Initiate	Buy
2021-09-23	Stifel	Initiate	Buy
2021-07-13	William Blair	Initiate	Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 9, 2024
Period: Q1 / 2024
EPS Estimate: -$0.37
Revenue Estimate
Revenue Q2Q: N/A
EPS Q2Q: 49.35%
Number of Analysts: 7

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

1.14%

EPS (3 Months)

5.30%

Next Earnings Summary

KNTE is expected to report earnings on 5/9/2024. The consensus EPS estimate for the next earnings is -0.37 USD and the consensus revenue estimate is 0 USD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
Revenue YoY % growth							N/A	N/A	N/A -100.00%	N/A	N/A 387.44%	N/A 77.60%	N/A 40.05%
EBITDA YoY % growth	N/A	N/A	-35.92M	-89.99M -150.53%	-117.92M -31.04%	-118.209M -0.25%	N/A 39.88%	N/A -5.97%	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-7.63M	-12.01M -57.40%	-36M -199.75%	-90.11M -150.31%	-118.52M -31.53%	-119.008M -0.41%	N/A 42.94%	N/A 0.27%	N/A -20.16%	N/A -17.40%	N/A 64.09%	N/A 158.11%	N/A 259.97%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS YoY % growth	N/A	N/A	N/A	-2.06 -27.42%	-2.65 -28.64%	-2.42 8.68%	N/A 47.95%	N/A 34.62%	N/A -59.75%	N/A 39.53%	N/A	N/A	N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 24	Q2 / 24	Q3 / 24	Q4 / 24	Q1 / 25	Q2 / 25	Q3 / 25	Q4 / 25
EPS Q2Q % growth	-0.37 49.35%	-0.35 48.25%	-0.33 48.61%	-0.28 22.56%	-0.33 11.72%	-0.33 7.25%	-0.30 11.45%	-0.30 -7.93%
Revenue Q2Q % growth					N/A	N/A	N/A	N/A
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	-18.474M 46.68%	-17.591M 48.47%	-16.391M 47.33%	-14.28M 25.25%	-20.196M -9.32%	-20.196M -14.81%	-20.196M -23.21%	-20.196M -41.43%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

13.35%

EPS Next 5 Year

13.70%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

N/A

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

KINNATE BIOPHARMA INC / KNTE Forecast FAQ

What is the average price target for KINNATE BIOPHARMA INC (KNTE) stock?

10 analysts have analysed KNTE and the average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65.

What is the next earnings date for KNTE stock?

KINNATE BIOPHARMA INC (KNTE) will report earnings on 2024-05-09, after the market close.

What are the consensus estimates for KNTE stock next earnings?

The consensus EPS estimate for the next earnings of KINNATE BIOPHARMA INC (KNTE) is -0.37 USD and the consensus revenue estimate is 0 USD.

Analyst forecast overview

Forecast Snapshot